BBH · VanEck

VanEck Biotech ETF

See how 25 reported holdings combine into this ETF’s P/E and P/S. Market value, signed ordinary earnings and revenue are added before each ratio is calculated.

Holdings dated 30 June 2026Price US$237.45 as of 2 October 2026Coverage limitations apply

Core valuation

Trailing P/E65.49×97.19% coverage

Latest-quarter run-rate P/E-73.89×97.19% coverage

Trailing P/S5.84×91.91% coverage

Latest-quarter run-rate P/S5.70×91.91% coverage

Coverage is the share of positive eligible-equity holding value represented in each metric. The published holdings account for 100.02% of fund weight. The reliability standard requires at least 90.00% disclosed fund weight and metric coverage, with no individual uncovered holding above 1.00%.

Largest reported holdings

Largest reported ETF holdings with weights and trailing valuation ratios
Holding	Weight	Trailing P/E	Trailing P/S
AMGNAmgen Inc	15.25%	25.18×	5.78×
GILDGilead Sciences Inc	12.79%	-56.45×	6.00×
VRTXVertex Pharmaceuticals Inc	9.10%	29.16×	10.20×
REGNRegeneron Pharmaceuticals Inc	6.21%	17.99×	5.01×
RVMDRevolution Medicines Inc	5.27%	-24.96×	Unavailable
ARGXArgenx SE	4.97%	38.91×	12.18×
NTRANatera Inc	4.92%	-306.11×	21.75×
IQVIQVIA Holdings Inc	4.31%	31.42×	2.62×
ALNYAlnylam Pharmaceuticals Inc	3.83%	39.93×	6.44×
BIIBBiogen Inc	3.63%	23.98×	3.31×

Top 10 of 25 reported holdings. * A holding uses its latest full-year result only when both trailing and latest-quarter inputs are unavailable; open the stock for the exact year end.

Most similar funds

Ranked by shared weight across matching disclosed company holdings and explicitly reported same-currency cash.

IBB · iShares Biotechnology ETF60.61% holdings overlap · US market
FBT · First Trust NYSE Arca Biotechnology Index Fund40.98% holdings overlap · NYSE Arca
IBBQ · Invesco Nasdaq Biotechnology ETF36.07% holdings overlap · US market
PBE · Invesco Biotechnology & Genome ETF36.07% holdings overlap · US market
BMED · iShares Health Innovation Active ETF34.44% holdings overlap · NYSE Arca

Sources and limitations

Holdings are sourced from VanEck and company financial inputs retain primary-source links. Monetary values are normalised to USD. Corporate actions, reporting lags, unmapped securities and cash can create differences from provider figures.

Open official holdings source

Research holdings date: 30 June 2026. Informational research, not investment advice.